Stoke Therapeutics, Inc. STOK
We are a late-stage clinical company dedicated to addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, we are developing antisense oligonucleotides ("ASOs") to selectively restore protein levels.
Our first investigational, new medicine in development, zorevunersen (STK-001), is a potential disease modifying medicine that is in late-stage clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is characterized by frequent, prolonged and refractory seizures beginning within the first year of life. The disease is classified as a developmental and epileptic encephalopathy due to the developmental delays and cognitive impairment associated with it. There are currently no disease modifying medicines approved for the treatment of Dravet syndrome.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | — | — | — | — | — |
| R&D | $137.9M | $89.1M | $82.2M | $77.8M | $54.2M | $32.2M | $23.8M | $8.4M | — |
| SG&A | $67.1M | $48.8M | $41.3M | $38.9M | $31.9M | $20.8M | $11.9M | $4.4M | — |
| Total operating expenses | $205.0M | $137.9M | $123.6M | $116.8M | $86.1M | $53.0M | $35.7M | $12.8M | — |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M | -$86.1M | -$53.0M | -$35.7M | -$12.8M | — |
| Interest expense | $9.0K | $26.0K | $49.0K | — | — | — | — | — | — |
| Pre-tax income | -$6.9M | — | — | — | — | — | — | — | — |
| Income tax | $0 | — | — | — | — | — | — | — | — |
| Net income | -$6.9M | -$89.0M | -$104.7M | -$101.1M | -$85.8M | -$52.2M | -$32.3M | -$12.5M | — |
| EPS, basic | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | — | — | — | — |
| EPS, diluted | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 | -1.56 | -1.80 | -17.65 | — |
| Shares, diluted (wtd. avg.) | 59.2M | 54.0M | 44.0M | 38.9M | 36.7M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $84.2M | $128.0M | $191.4M | $113.6M | $144.9M | $287.3M | $222.5M | $105.4M | — |
| Short-term investments | $200.4M | $88.9M | $10.0M | $116.0M | $74.9M | $0 | — | — | — |
| Receivables | $5.9M | $1.7M | — | — | — | — | — | — | — |
| Total current assets | $305.7M | $232.8M | $215.3M | $244.1M | $229.2M | $293.9M | $226.0M | $106.1M | — |
| Property, plant and equipment | $3.1M | $3.9M | $5.8M | $6.7M | $4.1M | $2.7M | $2.5M | $1.2M | — |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M | $238.9M | $297.9M | $228.8M | $107.5M | — |
| Accounts payable | $4.9M | $2.5M | $1.7M | $766.0K | $2.4M | $1.5M | $751.0K | $1.1M | — |
| Total current liabilities | $57.9M | $40.1M | $30.8M | $31.4M | $17.1M | $11.4M | $4.1M | $2.5M | — |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M | $21.1M | $11.8M | $4.3M | $2.5M | — |
| Retained earnings | -$497.7M | -$490.8M | -$401.8M | -$297.1M | -$196.1M | -$110.3M | -$58.0M | -$25.7M | — |
| Total equity | $352.5M | $229.0M | $159.6M | $184.8M | $217.8M | $286.1M | $224.4M | $105.1M | -$1.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $45.6M | -$86.9M | -$81.1M | -$31.9M | -$66.9M | -$42.2M | -$31.1M | -$11.0M | — |
| Depreciation and amortisation | $1.8M | $2.2M | $2.5M | $1.5M | $974.0K | $888.0K | $450.0K | $214.0K | — |
| Stock-based compensation | $32.2M | $27.5M | $25.3M | $22.9M | $16.4M | $5.8M | $1.9M | $240.0K | — |
| Capital expenditure | $670.0K | $203.0K | $1.6M | $4.0M | $1.2M | $1.1M | $1.6M | $935.0K | — |
| Investing cash flow | -$186.8M | -$107.5M | $105.9M | -$45.9M | -$76.4M | -$1.1M | -$1.6M | -$925.0K | — |
| Financing cash flow | $97.4M | $131.1M | $53.0M | $46.4M | $1.3M | $108.1M | $149.8M | $115.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-170362.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $12.4M | $8.8M | $36.6M | $184.4M |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$12.5M | -$32.3M | -$52.2M | -$85.8M | -$101.1M | -$104.7M | -$89.0M | -$6.9M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |